Liver fibrosis: cellular mechanisms of progression and resolution
The DOI matches its Crossref record; 137 of the 139 references it cites were found in a registry or an index.
Abstract
Liver fibrosis represents a major worldwide health care burden. The last 15 years have seen a rapid growth in our understanding of the pathogenesis of this clinically relevant model of inflammation and repair. This work is likely to inform the design of effective antifibrotic therapies in the near future. In this review, we examine how the innate and adaptive immune response interacts with other key cell types in the liver, such as the myofibroblast, regulating the process of hepatic fibrosis and, where relevant, resolution of fibrosis with remodelling. Emphasis is placed on the increasing knowledge that has been generated by the use of transgenic animals and animals in which specific cell lines have been deleted. Additionally, we review the increasing evidence that, although significant numbers of wound-healing myofibroblasts are derived from the hepatic stellate cell, significant contributions may occur from other cell lineages, including those from distant sites such as bone marrow stem cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity.”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [88]
In the citing paper
“Resolution of fibrosis involves not only the degradation of ECM but also reprogramming of the immune microenvironment (87, 88).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [88]
In the citing paper
“Fibrosis is regulated by an intricate interplay between TGF‐β pro‐fibrotic and TNF‐α anti‐fibrotic signaling pathways”
From p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling (2017) · cites this paper as Henderson & Iredale, 2007
Citations
Cites
1 retracted
RETRACTED: TGF-β1 induces alveolar epithelial to mesenchymal transition in vitro
Yao, H.-W., Xie, Q.-M., Chen, J., Deng, Y., & Tang, H. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.06.019 · Cited by 109
RetractedAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166
Michalopoulos, G. K., & DeFrances, M. C. (1997) · Science · doi:10.1126/science.276.5309.60 · Cited by 2,828
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 1×
“Duffield et al. (2005) [4]”
Self-citationEvidence that fibroblasts derive from epithelium during tissue fibrosis
Iwano, M., Plieth, D., Danoff, T. M., Xue, C., Okada, H., & Neilson, E. G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215518 · Cited by 1,590
The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum.
(1975) · PubMed Central · Cited by 1,437
Zeisberg, M., Hanai, J.-I., Sugimoto, H., Mammoto, T., Charytan, D., Strutz, F., & Kalluri, R. (2003) · Nature Medicine · doi:10.1038/nm888 · Cited by 1,346
Cited by
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Self-citationPathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Molecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Crosstalk between fibroblasts and inflammatory cells
Van Linthout, S., Miteva, K., & Tschope, C. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu062 · Cited by 569
Developmental origins of metabolic diseases
Hoffman, D. J., Powell, T. L., Barrett, E. S., & Hardy, D. B. (2021) · Physiological Reviews · doi:10.1152/physrev.00002.2020 · Cited by 466
Molecular mechanisms underlying chemical liver injury
Gu, X., & Manautou, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002110 · Cited by 381
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases
Soares, J.-B., Pimentel-Nunes, P., Roncon-Albuquerque, R., & Leite-Moreira, A. (2010) · Hepatology International · doi:10.1007/s12072-010-9219-x · Cited by 367
Developmental origins of health and disease: current knowledge and potential mechanisms
Hoffman, D. J., Reynolds, R. M., & Hardy, D. B. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux053 · Cited by 355
MicroRNAs in idiopathic pulmonary fibrosis
Pandit, K. V., Milosevic, J., & Kaminski, N. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.012 · Cited by 311
Liver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Barron, L., & Wynn, T. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00414.2010 · Cited by 304
Yosef, R., Pilpel, N., Papismadov, N., Gal, H., Ovadya, Y., Vadai, E., Miller, S., Porat, Z., Ben‐Dor, S., & Krizhanovsky, V. (2017) · The EMBO Journal · doi:10.15252/embj.201695553 · Cited by 293
Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation
Iredale, J. P., Thompson, A., & Henderson, N. C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.002 · Cited by 269
Self-citationMicroRNAs and the regulation of fibrosis
Jiang, X., Tsitsiou, E., Herrick, S. E., & Lindsay, M. A. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07632.x · Cited by 258
Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report
Blackwell, T. S., Tager, A. M., Borok, Z., Moore, B. B., Schwartz, D. A., Anstrom, K. J., Bar-Joseph, Z., Bitterman, P., Blackburn, M. R., Bradford, W., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1141ws · Cited by 236
The spatiotemporal program of zonal liver regeneration following acute injury
Ben-Moshe, S., Veg, T., Manco, R., Dan, S., Papinutti, D., Lifshitz, A., Kolodziejczyk, A. A., Bahar Halpern, K., Elinav, E., & Itzkovitz, S. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.04.008 · Cited by 224
“These could prove informative for the goals of resolving fibrotic states (Adler et al., 2020; Henderson and Iredale, 2007; Kisseleva and Brenner, 2006; Liu et al., 2020; Puche et al., 2013; Troeger et al., 2012).”
BackgroundIntegrin-mediated regulation of TGFβ in fibrosis
Henderson, N. C., & Sheppard, D. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.10.005 · Cited by 210
Self-citationMicroRNA-29 family, a crucial therapeutic target for fibrosis diseases
He, Y., Huang, C., Lin, X., & Li, J. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.010 · Cited by 193
Artaza, J. N., & Norris, K. C. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0241 · Cited by 186
Hu, N., Wang, C., Dai, X., Zhou, M., Gong, L., Yu, L., Peng, C., & Li, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112361 · Cited by 179
Wang, H., Haeger, S. M., Kloxin, A. M., Leinwand, L. A., & Anseth, K. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039969 · Cited by 179
Cancer-associated fibroblasts in hepatocellular carcinoma
Kubo, N., Araki, K., Kuwano, H., & Shirabe, K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6841 · Cited by 173
CXC chemokine ligand 4 (Cxcl4) is a platelet‐derived mediator of experimental liver fibrosis†
Zaldivar, M. M., Pauels, K., von Hundelshausen, P., Berres, M., Schmitz, P., Bornemann, J., Kowalska, M. A., Gassler, N., Streetz, K. L., Weiskirchen, R., et al. (2010) · Hepatology · doi:10.1002/hep.23435 · Cited by 171
Activation of stem cells in hepatic diseases
Bird, T. G., Lorenzini, S., & Forbes, S. J. (2008) · Cell and Tissue Research · doi:10.1007/s00441-007-0542-z · Cited by 170
Integrins and integrin-related proteins in cardiac fibrosis
Chen, C., Li, R., Ross, R. S., & Manso, A. M. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.010 · Cited by 162
S100A4 promotes liver fibrosis via activation of hepatic stellate cells
Chen, L., Li, J., Zhang, J., Dai, C., Liu, X., Wang, J., Gao, Z., Guo, H., Wang, R., Lu, S., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.035 · Cited by 162
MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4
He, Y., Huang, C. Z., Sun, X., Long, X., Lv, X., & Li, J. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.06.003 · Cited by 159
αv integrins: key regulators of tissue fibrosis
Conroy, K. P., Kitto, L. J., & Henderson, N. C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2407-9 · Cited by 147
Self-citationCorona-Directed Nucleic Acid Delivery into Hepatic Stellate Cells for Liver Fibrosis Therapy
Zhang, Z., Wang, C., Zha, Y., Hu, W., Gao, Z., Zang, Y., Chen, J., Zhang, J., & Dong, L. (2015) · ACS Nano · doi:10.1021/nn505166x · Cited by 138
Liver Myofibroblasts Regulate Infiltration and Positioning of Lymphocytes in Human Liver
Holt, A. P., Shepherd, E. L., Lalor, P. F., Filer, A. D., Buckley, C. D., & Adams, D. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.10.020 · Cited by 149
Reversibility of liver fibrosis
Pellicoro, A., Ramachandran, P., & Iredale, J. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s26 · Cited by 135
Self-citationThe Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer
Berasain, C., Perugorria, M. J., Latasa, M. U., Castillo, J., Goñi, S., Santamaría, M., Prieto, J., & Avila, M. A. (2009) · Experimental Biology and Medicine · doi:10.3181/0901-mr-12 · Cited by 132
Matrix Biology of Idiopathic Pulmonary Fibrosis
Thannickal, V. J., Henke, C. A., Horowitz, J. C., Noble, P. W., Roman, J., Sime, P. J., Zhou, Y., Wells, R. G., White, E. S., & Tschumperlin, D. J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.02.003 · Cited by 117
Ectopic SOX9 Mediates Extracellular Matrix Deposition Characteristic of Organ Fibrosis
Piper Hanley, K., Oakley, F., Sugden, S., Wilson, D. I., Mann, D. A., & Hanley, N. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707390200 · Cited by 120
Wu, Y., Liu, X., Zhou, Q. Y., Huang, C., Meng, X., Xu, F., & Li, J. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.09.028 · Cited by 121
Chung, S. I., Moon, H., Ju, H.-L., Cho, K. J., Kim, D. Y., Han, K.-H., Eun, J. W., Nam, S. W., Ribback, S., Dombrowski, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.007 · Cited by 117
Gu, L., Tao, X., Xu, Y., Han, X., Qi, Y., Xu, L., Yin, L., & Peng, J. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.12.024 · Cited by 118
Stewart, R. K., Dangi, A., Huang, C., Murase, N., Kimura, S., Stolz, D. B., Wilson, G. C., Lentsch, A. B., & Gandhi, C. R. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.013 · Cited by 117
Hepatic Stellate Cells May Relate to Progression of Intrahepatic Cholangiocarcinoma
Okabe, H., Beppu, T., Hayashi, H., Horino, K., Masuda, T., Komori, H., Ishikawa, S., Watanabe, M., Takamori, H., Iyama, K.-I., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0568-4 · Cited by 111
The potential of microRNAs in liver fibrosis
He, Y., Huang, C. Z., Zhang, S., Sun, X., Long, X., & Li, J. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.07.023 · Cited by 116
Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats
Tsai, M.-K., Lin, Y., & Huang, Y. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.10.002 · Cited by 117
Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection
Mastroianni, C. M., Lichtner, M., Mascia, C., Zuccalà, P., & Vullo, V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069184 · Cited by 115
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress
Vairappan, B. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.443 · Cited by 105
Cardiac valve cells and their microenvironment—insights from in vitro studies
Wang, H., Leinwand, L. A., & Anseth, K. S. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.162 · Cited by 104
Hepatic stellate cells: central modulators of hepatic carcinogenesis
Thompson, A. I., Conroy, K. P., & Henderson, N. C. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0291-5 · Cited by 100
Self-citationPathogenesis of fibrostenosing Crohn's disease
Li, J., Mao, R., Kurada, S. V., Wang, J., Lin, S., Chandra, J., & Rieder, F. (2019) · Translational research · doi:10.1016/j.trsl.2019.03.005 · Cited by 111
Immune Interactions in Hepatic Fibrosis
Holt, A. P., Salmon, M., Buckley, C. D., & Adams, D. H. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.002 · Cited by 101
Betulin alleviated ethanol-induced alcoholic liver injury via SIRT1/AMPK signaling pathway
Bai, T., Yang, Y., Yao, Y., Sun, P., Lian, L., Wu, Y., & Nan, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.022 · Cited by 100
Repair‐related activation of hedgehog signaling promotes cholangiocyte chemokine production†
Omenetti, A., Syn, W., Jung, Y., Francis, H., Porrello, A., Witek, R. P., Choi, S. S., Yang, L., Mayo, M. J., Gershwin, M. E., et al. (2009) · Hepatology · doi:10.1002/hep.23019 · Cited by 101
Reversibility of liver fibrosis
Ramachandran, P., & Iredale, J. P. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31740-5 · Cited by 98
Self-citationAntibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury
Douglass, A., Wallace, K., Parr, R., Park, J., Durward, E., Broadbent, I. D., Barelle, C. J., Porter, A. J., & Wright, M. C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.032 · Cited by 90
New dog and new tricks: evolving roles for IL-33 in type 2 immunity
Lott, J. M., Sumpter, T. L., & Turnquist, H. R. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri1214-595r · Cited by 91
Advances in antifibrotic therapy
Ghiassi–Nejad, Z., & Friedman, S. L. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.6.803 · Cited by 88
Okabe, H., Beppu, T., Ueda, M., Hayashi, H., Ishiko, T., Masuda, T., Otao, R., Horlad, H., Mima, K., Miyake, K., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27496 · Cited by 84
Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model
Wang, X., Gong, G., Yang, W.-H., Li, Y., Jiang, M., & Li, L. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.04.004 · Cited by 81
Mesenchymal stromal cells and liver fibrosis: a complicated relationship
Haldar, D., Henderson, N. C., Hirschfield, G., & Newsome, P. N. (2016) · The FASEB Journal · doi:10.1096/fj.201600433r · Cited by 80
Self-citationDefining therapeutic targets for liver fibrosis: Exploiting the biology of inflammation and repair
Iredale, J. P. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.011 · Cited by 90
Self-citationZhuang, T., Gu, X., Zhou, N., Ding, L., Yang, L., & Zhou, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110224 · Cited by 91
Yovchev, M. I., Xue, Y., Shafritz, D. A., Locker, J., & Oertel, M. (2014) · Hepatology · doi:10.1002/hep.26615 · Cited by 73
The Therapeutic Potential of MicroRNAs: Disease Modulators and Drug Targets
McDermott, A. M., Heneghan, H., Miller, N., & Kerin, M. J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0550-2 · Cited by 78
The roles of lncRNA in hepatic fibrosis
Peng, H., Wan, L., Liang, J.-J., Zhang, Y., Ai, W., & Wu, J. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0259-6 · Cited by 73
The non-invasive assessment of hepatic fibrosis
Gheorghe, G., BUNGAU, S. G., Ceobanu, G., Ilie, M., Bacalbașa, N., Bratu, O. G., Vesa, C. M., Găman, M., & Diaconu, C. C. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.08.019 · Cited by 71
Wang, C., Ma, C., Fu, K., Gong, L., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.756924 · Cited by 69
Fibroblast activation protein and chronic liver disease
Wang, X. M., Yao, T.-W., Nadvi, N. A., Osborne, B., McCaughan, G. W., & Gorrell, M. D. (2007) · Frontiers in bioscience · doi:10.2741/2918 · Cited by 73
Wang, C., Liu, Q., Huang, Q., Liu, J. T., He, Y. H., Lu, J., & Bai, X. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.02.001 · Cited by 69
Coagulation and fibrosis in chronic liver disease
Calvaruso, V., Maimone, S., Gatt, A., Tuddenham, E. G. D., Thursz, M. R., Pinzani, M., & Burroughs, A. K. (2008) · Gut · doi:10.1136/gut.2008.150748 · Cited by 67
Shao, S. H., Duan, W., Xu, Q., Li, X., Han, L., Li, W., Zhang, D., Wang, Z., & Lei, J. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8148510 · Cited by 69
Said, M. M., Azab, S. S., Saeed, N. M., & El-Demerdash, E. (2018) · Annals of Hepatology · doi:10.5604/01.3001.0010.8662 · Cited by 65
Yuan, Y., Wang, Y., Wang, R., Wang, Y., Peng, R., & Wu, Y. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s93732 · Cited by 72
Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development
Ogawa, S., Ochi, T., Shimada, H., Inagaki, K., Fujita, I., Nii, A., Moffat, M. A., Katragadda, M., Violand, B. N., Arch, R. H., et al. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00718.x · Cited by 62
Experimental obstructive cholestasis: the wound-like inflammatory liver response
Aller, M., Arias, J.-L., García-Domínguez, J., Árias, J., Durán, M., & Árias, J. (2008) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-1-6 · Cited by 74
Hepatic fibrogenesis: From within and outwith
Henderson, N. C., & Forbes, S. J. (2008) · Toxicology · doi:10.1016/j.tox.2008.08.017 · Cited by 71
Self-citationProfibrotic effect of miR-33a with Akt activation in hepatic stellate cells
Li, Z., Ou-Yang, P.-H., & Han, X.-P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.09.018 · Cited by 66
Pan, R., Wang, P., Xiang, L., & Shao, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.194498 · Cited by 63
Engineering in vitro models of hepatofibrogenesis
Mazza, G., Al‐Akkad, W., & Rombouts, K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.018 · Cited by 65
Profibrotic Role of Myostatin in Peyronie's Disease
Cantini, L. P., Ferrini, M. G., Vernet, D., Magee, T. R., Qian, A., Gelfand, R. A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00847.x · Cited by 59
Suppression of SUN2 by DNA methylation is associated with HSCs activation and hepatic fibrosis
Chen, X., Li, W., Chen, Y., Li, X., Li, H.-D., Huang, H., Bu, F., Pan, X., Yang, Y., Huang, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1032-9 · Cited by 61
Blaas, L., Kornfeld, J., Schramek, D., Musteanu, M., Zollner, G., Gumhold, J., van Zijl, F., Schneller, D., Esterbauer, H., Egger, G., et al. (2009) · Hepatology · doi:10.1002/hep.23469 · Cited by 62
Zou, Y., Cai, Y., Lu, D., Zhou, Y., Yao, Q., & Zhang, S. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.07.016 · Cited by 63
Hu, N., Guo, C., Dai, X., Wang, C., Gong, L., Yu, L., Peng, C. Y., & Li, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113275 · Cited by 63
He, F., Guo, F., Li, Z., Yu, H., Ma, P., Zhao, J., Feng, L., Li, W., Liu, X., Qin, H., et al. (2015) · Hepatology · doi:10.1002/hep.27394 · Cited by 54
Kim, M., Park, S.-A., Kim, C. H., Park, S.-Y., Kim, J.-S., Kim, D., Nam, J., & Sheen, Y. Y. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000438651 · Cited by 54
Zhang, C., Wang, L., Ali, T., Li, L., Bi, X., Wang, J., Lü, G., Shao, Y., Vuitton, D. A., Wen, H., et al. (2016) · Parasites & Vectors · doi:10.1186/s13071-016-1562-x · Cited by 56
Adverse outcome pathway development from protein alkylation to liver fibrosis
Horvat, T., Landesmann, B., Lostia, A., Vinken, M., Munn, S., & Whelan, M. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1814-8 · Cited by 53
Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives
Mahdinloo, S., Kiaie, S. H., Amiri, A., Hemmati, S., Valizadeh, H., & Zakeri‐Milani, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.03.007 · Cited by 56
Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats
Hessin, A. F., Hegazy, R. R., Hassan, A. H. M., Yassin, N., & Kenawy, S. A. (2015) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2015.038 · Cited by 52
Pan, R., Xiang, L., Wang, P., Liu, X., Nie, L., Huang, W., & Shao, J. (2014) · Hepatology · doi:10.1002/hep.27649 · Cited by 51
Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats
Shin, J., Wang, J., Kang, J., & Son, C. (2009) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.3838 · Cited by 50
Chow, L. N. Y., Schreiner, P., Ng, B. Y. Y., Lo, B. C., Hughes, M. R., Scott, R. W., Gusti, V., Lecour, S., Simonson, E., Manisali, I., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151765 · Cited by 53
Hepatoprotective Influence of Vitamin C on Thioacetamide-induced Liver Cirrhosis in Wistar Male Rats
Al-Attar, A. M. (2011) · Journal of Pharmacology and Toxicology · doi:10.3923/jpt.2011.218.233 · Cited by 50
Li, J., Liu, P., Zhang, R., Cao, L., Qian, H., Liao, J., Xu, W., Wu, M., & Yin, Z.-F. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.06.030 · Cited by 50
Duval, F., Moreno-Cuevas, J. E., González‐Garza, M. T., Rodriguez-Montalvo, C. A., & Cruz‐Vega, D. E. (2014) · Advances in Pharmacological Sciences · doi:10.1155/2014/373295 · Cited by 49
Duval, F., Moreno-Cuevas, J. E., González‐Garza, M. T., Maldonado‐Bernal, C., & Cruz‐Vega, D. E. (2015) · International Journal of Inflammation · doi:10.1155/2015/943497 · Cited by 54
Hasan, H. F., Abdel-Rafei, M. K., & Galal, S. M. (2016) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0142 · Cited by 51
Choi, J. H., Hwang, Y. P., Choi, C. Y., Chung, Y., & Jeong, H. G. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.08.009 · Cited by 49
Artaza, J. N., Singh, R., Ferrini, M. G., Braga, M., Tsao, J., & Gonzalez-Cadavid, N. F. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0408 · Cited by 51
Pritchard, M. T., & Nagy, L. E. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091186 · Cited by 50
Zhang, Y., Miao, H., Yan, H., Sheng, Y., & Ji, L. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.02.033 · Cited by 48
Metadata
- Authors
- Henderson, N. C., & Iredale, J. P.
- Affiliations
- Centre for Inflammation Research (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2007-02-01
- Volume
- 112
- Issue
- 5
- Pages
- 265-280
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W1976809932
- Cited by
- 270
- References
- 139
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 3 · 2021: 15 · 2020: 11 · 2019: 10 · 2018: 15 · 2017: 13 · 2016: 23 · 2015: 25 · 2014: 19 · 2013: 15 · 2012: 20
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liver fibrosis, fibrosis resolution, myofibroblasts, hepatic stellate cells, wound healing, innate immune response, adaptive immune response, antifibrotic therapy, transgenic animal models, lineage tracing, bone marrow-derived stem cells, liver regeneration
- MeSH terms
- Animals, Disease Models, Animal, Fibroblasts, Humans, Immunity, Cellular, Liver Cirrhosis, Prognosis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.